<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Balko, Justin M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Profiling Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Targetable Genetic Alterations</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-8</style></pages><abstract><style  face="normal" font="default" size="100%">Neoadjuvant chemotherapy (NACT) is now widely used in the management of locally advanced breast cancer and in patients with relatively large tumors who are interested in breast conservation. Patients who do not have a complete pathologic complete response typically have poorer outcomes compared with patients with a pCR [Rastogi P et al. J Clin Oncol 2008]. This article presents molecular profiling data on residual triple-negative breast cancer after NACT.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>